- Home
- GTBP vs APM Comparison
GTBP vs APM Comparison
Compare GTBP & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTBP
- APM
- Stock Information
- Founded
- GTBP 1965
- APM 2010
- Country
- GTBP United States
- APM United Kingdom
- Employees
- GTBP N/A
- APM N/A
- Industry
- GTBP Biotechnology: Pharmaceutical Preparations
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- GTBP Health Care
- APM Health Care
- Exchange
- GTBP Nasdaq
- APM Nasdaq
- Market Cap
- GTBP 5.5M
- APM 5.6M
- IPO Year
- GTBP N/A
- APM 2018
- Fundamental
- Price
- GTBP $2.28
- APM $0.99
- Analyst Decision
- GTBP Strong Buy
- APM
- Analyst Count
- GTBP 1
- APM 0
- Target Price
- GTBP $11.00
- APM N/A
- AVG Volume (30 Days)
- GTBP 14.8K
- APM 138.3K
- Earning Date
- GTBP 05-14-2025
- APM 05-06-2025
- Dividend Yield
- GTBP N/A
- APM N/A
- EPS Growth
- GTBP N/A
- APM N/A
- EPS
- GTBP N/A
- APM 0.00
- Revenue
- GTBP N/A
- APM N/A
- Revenue This Year
- GTBP N/A
- APM $157,729.10
- Revenue Next Year
- GTBP N/A
- APM N/A
- P/E Ratio
- GTBP N/A
- APM $270.99
- Revenue Growth
- GTBP N/A
- APM N/A
- 52 Week Low
- GTBP $1.72
- APM $0.46
- 52 Week High
- GTBP $10.66
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- GTBP 48.56
- APM 51.54
- Support Level
- GTBP $2.15
- APM $0.79
- Resistance Level
- GTBP $2.38
- APM $0.97
- Average True Range (ATR)
- GTBP 0.17
- APM 0.12
- MACD
- GTBP -0.01
- APM 0.02
- Stochastic Oscillator
- GTBP 32.35
- APM 33.74
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.